Plain-English translation of NCT04185272 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying special proteins called butyrophilins in colon cancer tissue to see if these proteins can be used as markers to predict how aggressive a patient's cancer might be. This is basic research—meaning the scientists are trying to understand the disease better, not testing a new drug. By analyzing tissue samples from 200 patients with colon cancer, they hope to find a way to help doctors identify which cancers are more likely to spread.
Right now, doctors don't have reliable ways to predict which colon cancers will be more aggressive. If researchers can show that butyrophilins are linked to cancer aggressiveness, this could help doctors personalize treatment plans and improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you qualify, your participation would involve providing tissue samples during your already-planned colon cancer surgery. Researchers will analyze these samples to measure the butyrophilin proteins and determine if they can predict cancer aggressiveness. There are no extra visits or procedures beyond your standard surgical care.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
France
Sponsor
Institut Paoli-Calmettes
Enrollment target
~200 participants
Started
June 2020
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jihane PAKRADOUNI, PharmD,PhD
Institut Paoli-Calmettes
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.